25 XP   0   0   10

Xenon Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Xenon Pharmaceuticals Inc together

PenkeI guess you are interested in Xenon Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Xenon Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Xenon Pharmaceuticals Inc

I send you an email if I find something interesting about Xenon Pharmaceuticals Inc.

Quick analysis of Xenon Pharmaceuticals Inc (30 sec.)










What can you expect buying and holding a share of Xenon Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$12.30
Expected worth in 1 year
$15.04
How sure are you?
35.0%

+ What do you gain per year?

Total Gains per Share
$2.74
Return On Investment
6.8%

For what price can you sell your share?

Current Price per Share
$40.50
Expected price per share
$27.99 - $44.63
How sure are you?
50%

1. Valuation of Xenon Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)

$40.50

Intrinsic Value Per Share

$-22.90 - $-12.43

Total Value Per Share

$-10.60 - $-0.13

2. Growth of Xenon Pharmaceuticals Inc (5 min.)




Is Xenon Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$927.9m$700.5m$23.9m3.3%

How much money is Xenon Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$45.5m-$31.3m-$14.2m-31.3%
Net Profit Margin-207.9%-115,193.2%--

How much money comes from the company's main activities?

3. Financial Health of Xenon Pharmaceuticals Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#62 / 1010

Most Revenue
#474 / 1010

Most Profit
#876 / 1010

Most Efficient
#632 / 1010

What can you expect buying and holding a share of Xenon Pharmaceuticals Inc? (5 min.)

Welcome investor! Xenon Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Xenon Pharmaceuticals Inc.

What can you expect buying and holding a share of Xenon Pharmaceuticals Inc?

First you should know what it really means to hold a share of Xenon Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Xenon Pharmaceuticals Inc is $40.50. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Xenon Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Xenon Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $12.30. Based on the TTM, the Book Value Change Per Share is $0.68 per quarter. Based on the YOY, the Book Value Change Per Share is $0.57 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Xenon Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.59-1.5%-0.60-1.5%-0.41-1.0%-0.30-0.7%-0.18-0.4%
Usd Book Value Change Per Share3.869.5%0.681.7%0.571.4%0.551.3%0.300.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share3.869.5%0.681.7%0.571.4%0.551.3%0.300.7%
Usd Price Per Share46.06-38.63-34.13-23.33-15.16-
Price to Earnings Ratio-19.41--16.04--21.61--88.99--40.57-
Price-to-Total Gains Ratio11.93--99.79--112.47--35.81-98.63-
Price to Book Ratio3.74-4.05-3.73-5.42-6.93-
Price-to-Total Gains Ratio11.93--99.79--112.47--35.81-98.63-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share40.5
Number of shares24
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.680.55
Usd Total Gains Per Share0.680.55
Gains per Quarter (24 shares)16.4213.12
Gains per Year (24 shares)65.6852.47
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10665605242
20131122010594
301971880157146
402632540210198
503283200262250
603943860315302
704604520367354
805255180420406
905915840472458
1006576500525510

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%5.035.00.012.5%7.035.01.016.3%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%7.013.00.035.0%14.025.01.035.0%16.025.02.037.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.043.00.0%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%7.013.00.035.0%14.025.01.035.0%16.025.02.037.2%

Fundamentals of Xenon Pharmaceuticals Inc

About Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.

Fundamental data was last updated by Penke on 2024-04-12 22:41:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Xenon Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Xenon Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Xenon Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -831.7% means that $-8.32 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Xenon Pharmaceuticals Inc:

  • The MRQ is -831.7%. The company is making a huge loss. -2
  • The TTM is -207.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-831.7%TTM-207.9%-623.7%
TTM-207.9%YOY-115,193.2%+114,985.3%
TTM-207.9%5Y-23,245.7%+23,037.8%
5Y-23,245.7%10Y-16,091.3%-7,154.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-831.7%-207.2%-624.5%
TTM-207.9%-216.8%+8.9%
YOY-115,193.2%-282.3%-114,910.9%
5Y-23,245.7%-436.8%-22,808.9%
10Y-16,091.3%-597.3%-15,494.0%
1.1.2. Return on Assets

Shows how efficient Xenon Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Xenon Pharmaceuticals Inc to the Biotechnology industry mean.
  • -4.6% Return on Assets means that Xenon Pharmaceuticals Inc generated $-0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Xenon Pharmaceuticals Inc:

  • The MRQ is -4.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-4.6%TTM-6.1%+1.5%
TTM-6.1%YOY-4.3%-1.9%
TTM-6.1%5Y-5.8%-0.4%
5Y-5.8%10Y-6.1%+0.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.6%-13.3%+8.7%
TTM-6.1%-12.8%+6.7%
YOY-4.3%-11.6%+7.3%
5Y-5.8%-13.8%+8.0%
10Y-6.1%-15.6%+9.5%
1.1.3. Return on Equity

Shows how efficient Xenon Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Xenon Pharmaceuticals Inc to the Biotechnology industry mean.
  • -4.8% Return on Equity means Xenon Pharmaceuticals Inc generated $-0.05 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Xenon Pharmaceuticals Inc:

  • The MRQ is -4.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -6.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-4.8%TTM-6.5%+1.6%
TTM-6.5%YOY-4.4%-2.0%
TTM-6.5%5Y-6.7%+0.2%
5Y-6.7%10Y-6.7%+0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.8%-16.9%+12.1%
TTM-6.5%-16.1%+9.6%
YOY-4.4%-14.9%+10.5%
5Y-6.7%-19.3%+12.6%
10Y-6.7%-20.1%+13.4%

1.2. Operating Efficiency of Xenon Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Xenon Pharmaceuticals Inc is operating .

  • Measures how much profit Xenon Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Xenon Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of -998.0% means the company generated $-9.98  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Xenon Pharmaceuticals Inc:

  • The MRQ is -998.0%. The company is operating very inefficient. -2
  • The TTM is -249.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-998.0%TTM-249.5%-748.5%
TTM-249.5%YOY-133,730.3%+133,480.8%
TTM-249.5%5Y-26,961.1%+26,711.5%
5Y-26,961.1%10Y-18,841.0%-8,120.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-998.0%-298.0%-700.0%
TTM-249.5%-238.5%-11.0%
YOY-133,730.3%-288.4%-133,441.9%
5Y-26,961.1%-486.2%-26,474.9%
10Y-18,841.0%-628.4%-18,212.6%
1.2.2. Operating Ratio

Measures how efficient Xenon Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 9.98 means that the operating costs are $9.98 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Xenon Pharmaceuticals Inc:

  • The MRQ is 9.980. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.495. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ9.980TTM2.495+7.485
TTM2.495YOY1,404.123-1,401.628
TTM2.4955Y283.504-281.009
5Y283.50410Y233.283+50.221
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.9803.235+6.745
TTM2.4953.310-0.815
YOY1,404.1233.838+1,400.285
5Y283.5045.679+277.825
10Y233.2837.823+225.460

1.3. Liquidity of Xenon Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Xenon Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 23.65 means the company has $23.65 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Xenon Pharmaceuticals Inc:

  • The MRQ is 23.648. The company is very able to pay all its short-term debts. +2
  • The TTM is 22.041. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ23.648TTM22.041+1.608
TTM22.041YOY48.611-26.570
TTM22.0415Y23.137-1.096
5Y23.13710Y18.569+4.567
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ23.6483.863+19.785
TTM22.0414.169+17.872
YOY48.6115.337+43.274
5Y23.1376.122+17.015
10Y18.5696.434+12.135
1.3.2. Quick Ratio

Measures if Xenon Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Xenon Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 41.37 means the company can pay off $41.37 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Xenon Pharmaceuticals Inc:

  • The MRQ is 41.374. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 39.984. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ41.374TTM39.984+1.390
TTM39.984YOY83.476-43.492
TTM39.9845Y39.634+0.350
5Y39.63410Y28.958+10.676
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ41.3743.504+37.870
TTM39.9843.991+35.993
YOY83.4765.371+78.105
5Y39.6346.088+33.546
10Y28.9586.395+22.563

1.4. Solvency of Xenon Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Xenon Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Xenon Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.04 means that Xenon Pharmaceuticals Inc assets are financed with 3.8% credit (debt) and the remaining percentage (100% - 3.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Xenon Pharmaceuticals Inc:

  • The MRQ is 0.038. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.048. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.038TTM0.048-0.010
TTM0.048YOY0.032+0.016
TTM0.0485Y0.103-0.055
5Y0.10310Y0.135-0.033
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0380.339-0.301
TTM0.0480.337-0.289
YOY0.0320.271-0.239
5Y0.1030.368-0.265
10Y0.1350.388-0.253
1.4.2. Debt to Equity Ratio

Measures if Xenon Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Xenon Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 4.0% means that company has $0.04 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Xenon Pharmaceuticals Inc:

  • The MRQ is 0.040. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.050. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.040TTM0.050-0.011
TTM0.050YOY0.033+0.017
TTM0.0505Y0.129-0.079
5Y0.12910Y0.191-0.062
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0400.392-0.352
TTM0.0500.403-0.353
YOY0.0330.335-0.302
5Y0.1290.427-0.298
10Y0.1910.461-0.270

2. Market Valuation of Xenon Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Xenon Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Xenon Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -19.41 means the investor is paying $-19.41 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Xenon Pharmaceuticals Inc:

  • The EOD is -17.070. Based on the earnings, the company is expensive. -2
  • The MRQ is -19.413. Based on the earnings, the company is expensive. -2
  • The TTM is -16.045. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-17.070MRQ-19.413+2.343
MRQ-19.413TTM-16.045-3.369
TTM-16.045YOY-21.614+5.569
TTM-16.0455Y-88.993+72.948
5Y-88.99310Y-40.573-48.419
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-17.070-2.300-14.770
MRQ-19.413-2.656-16.757
TTM-16.045-2.718-13.327
YOY-21.614-4.145-17.469
5Y-88.993-6.258-82.735
10Y-40.573-6.315-34.258
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Xenon Pharmaceuticals Inc:

  • The EOD is -22.669. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -25.781. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -19.896. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-22.669MRQ-25.781+3.112
MRQ-25.781TTM-19.896-5.885
TTM-19.896YOY-26.887+6.992
TTM-19.8965Y-20.156+0.261
5Y-20.15610Y-23.117+2.961
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-22.669-2.974-19.695
MRQ-25.781-3.306-22.475
TTM-19.896-3.508-16.388
YOY-26.887-5.613-21.274
5Y-20.156-8.378-11.778
10Y-23.117-8.873-14.244
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Xenon Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.74 means the investor is paying $3.74 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Xenon Pharmaceuticals Inc:

  • The EOD is 3.292. Based on the equity, the company is fair priced.
  • The MRQ is 3.744. Based on the equity, the company is fair priced.
  • The TTM is 4.054. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.292MRQ3.744-0.452
MRQ3.744TTM4.054-0.309
TTM4.054YOY3.729+0.325
TTM4.0545Y5.423-1.369
5Y5.42310Y6.930-1.508
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.2921.914+1.378
MRQ3.7442.116+1.628
TTM4.0542.097+1.957
YOY3.7292.881+0.848
5Y5.4233.550+1.873
10Y6.9303.936+2.994
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Xenon Pharmaceuticals Inc.

3.1. Institutions holding Xenon Pharmaceuticals Inc

Institutions are holding 99.975% of the shares of Xenon Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31venBio Select Advisor LLC7.51223.6052566666676666615.6462
2023-12-31FMR Inc7.4980.025655922140305632.9908
2023-12-31Driehaus Capital Management LLC5.76042.41114345180-167825-3.7187
2023-12-31Wellington Management Company LLP5.51840.035841626542434546140.8793
2023-12-31Polar Capital Holdings PLC4.06540.86533066628628812.0934
2023-12-31Capital World Investors3.55490.022268153740656317.8711
2023-12-31Capital Research & Mgmt Co - Division 33.25550.0254245568388630.3622
2023-12-31COMMODORE CAPITAL LP2.87388.7245216779332279317.4956
2023-12-31Paradigm Biocapital Advisors LP2.82034.5876212740063556542.6029
2023-09-30BRAIDWELL LP2.78842.2707210339627504315.0432
2023-12-31BlackRock Inc2.74030.002420670631075606108.4874
2023-12-31Pictet Asset Manangement SA2.70490.103720404001016215.2415
2023-09-30Bvf Inc2.42331.6838182795800
2023-12-31First Light Asset Management, LLC2.18146.097616454901043420173.3054
2023-12-31AllianceBernstein L.P.2.08740.0279157456849023145.2102
2023-12-31Marshall Wace Asset Management Ltd2.02650.11931528648-625746-29.0451
2023-12-31Rock Springs Capital Management LP1.66451.42371255577775756.5853
2023-09-30Point72 Asset Management, L.P.1.49230.11221125708977500659.546
2023-12-31Perceptive Advisors LLC1.45921.1317110074848324878.2588
2023-12-31Adage Capital Partners Gp LLC1.39030.1104872549872590.6773
Total 65.817433.369949647744+10270331+20.7%

3.2. Funds holding Xenon Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31American Funds SMALLCAP World A6.80970.328851366904154268.799
2023-12-31Vanguard Health Care Inv3.37030.252325423371921710309.6401
2024-02-29Polar Capital Biotech S Inc1.95543.959147500000
2024-02-29Fidelity Select Health Care1.59080.7156120000000
2023-12-31Pictet-Biotech P USD1.26152.7748951570-253353-21.0265
2024-02-29Fidelity Advisor Health Care I1.0340.739878000000
2024-02-29Polar Capital Healthcare Opports Inc0.98362.0788741950-364730-32.9571
2023-12-31Pictet-Global Megatrend Sel I USD0.77040.2132581119451432348.0935
2024-02-29Strategic Advisers Fidelity US TtlStk0.75760.0255571495124202.2215
2024-03-31Bridge Builder Small/Mid Cap Growth0.73910.279955748400
2024-02-29Lord Abbett Developing Growth A0.72151.028354423311371026.4121
2024-03-28iShares Biotechnology ETF0.71810.3056541708-2126-0.3909
2024-02-29Fidelity Select Biotechnology0.71540.518153963400
2024-02-29Candriam Eqs L Biotech C USD Cap0.70381.524653088400
2024-02-29Fidelity Advisor Biotechnology I0.65641.314349515800
2024-01-31Fidelity Series Small Cap Opps0.62950.415474830-4500-0.9388
2024-02-29AB Small Cap Growth A0.62280.5517469766-32308-6.4349
2024-02-29Wellington Global Hlthcr Eq USD G Ac0.59590.8073449506-13125-2.837
2024-02-29BlackRock Health Sciences Opps Inv A0.5940.249544809900
2024-02-29BlackRock Health Sciences Term Trust0.55691.016742008400
Total 25.786719.098819451547+2244556+11.5%

3.3. Insider Transactions

Insiders are holding 0.377% of the shares of Xenon Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-07Sherrington RobinSELL713746.28
2024-03-07Steven GannonSELL1300046.28
2023-12-13Gary PatouSELL1138039.29
2023-08-24Dawn SvoronosSELL2500038.7
2023-05-31Simon N PimstoneSELL6252638.7
2023-05-24Ian MortimerSELL3165541.41

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Xenon Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--3.8620.684+465%0.568+580%0.547+607%0.300+1189%
Book Value Per Share--12.3019.604+28%9.287+32%5.372+129%3.065+301%
Current Ratio--23.64822.041+7%48.611-51%23.137+2%18.569+27%
Debt To Asset Ratio--0.0380.048-20%0.032+19%0.103-63%0.135-72%
Debt To Equity Ratio--0.0400.050-21%0.033+20%0.129-69%0.191-79%
Dividend Per Share----0%-0%-0%-0%
Eps---0.593-0.604+2%-0.414-30%-0.300-49%-0.181-69%
Free Cash Flow Per Share---0.447-0.494+11%-0.336-25%-0.251-44%-0.160-64%
Free Cash Flow To Equity Per Share--3.8050.667+471%0.587+548%0.538+608%0.295+1188%
Gross Profit Margin--1.0191.005+1%1.000+2%1.001+2%1.000+2%
Intrinsic Value_10Y_max---12.429--------
Intrinsic Value_10Y_min---22.898--------
Intrinsic Value_1Y_max---0.729--------
Intrinsic Value_1Y_min---1.581--------
Intrinsic Value_3Y_max---2.583--------
Intrinsic Value_3Y_min---5.396--------
Intrinsic Value_5Y_max---4.912--------
Intrinsic Value_5Y_min---9.891--------
Market Cap3055016088.000-14%3474420765.7602913768739.240+19%2574511088.480+35%1759613834.192+97%1143198335.004+204%
Net Profit Margin---8.317-2.079-75%-1151.932+13751%-232.457+2695%-160.913+1835%
Operating Margin---9.980-2.495-75%-1337.303+13299%-269.611+2601%-188.410+1788%
Operating Ratio--9.9802.495+300%1404.123-99%283.504-96%233.283-96%
Pb Ratio3.292-14%3.7444.054-8%3.729+0%5.423-31%6.930-46%
Pe Ratio-17.070+12%-19.413-16.045-17%-21.614+11%-88.993+358%-40.573+109%
Price Per Share40.500-14%46.06038.628+19%34.130+35%23.327+97%15.155+204%
Price To Free Cash Flow Ratio-22.669+12%-25.781-19.896-23%-26.887+4%-20.156-22%-23.117-10%
Price To Total Gains Ratio10.486-14%11.926-99.785+937%-112.474+1043%-35.808+400%98.631-88%
Quick Ratio--41.37439.984+3%83.476-50%39.634+4%28.958+43%
Return On Assets---0.046-0.061+33%-0.043-8%-0.058+25%-0.061+31%
Return On Equity---0.048-0.065+34%-0.044-8%-0.067+38%-0.067+39%
Total Gains Per Share--3.8620.684+465%0.568+580%0.547+607%0.300+1189%
Usd Book Value--927921000.000724478500.000+28%700565500.000+32%405235150.000+129%231174350.000+301%
Usd Book Value Change Per Share--3.8620.684+465%0.568+580%0.547+607%0.300+1189%
Usd Book Value Per Share--12.3019.604+28%9.287+32%5.372+129%3.065+301%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.593-0.604+2%-0.414-30%-0.300-49%-0.181-69%
Usd Free Cash Flow---33691729.510-37273182.378+11%-25331000.000-25%-18930086.476-44%-12065918.238-64%
Usd Free Cash Flow Per Share---0.447-0.494+11%-0.336-25%-0.251-44%-0.160-64%
Usd Free Cash Flow To Equity Per Share--3.8050.667+471%0.587+548%0.538+608%0.295+1188%
Usd Market Cap3055016088.000-14%3474420765.7602913768739.240+19%2574511088.480+35%1759613834.192+97%1143198335.004+204%
Usd Price Per Share40.500-14%46.06038.628+19%34.130+35%23.327+97%15.155+204%
Usd Profit---44743000.000-45598250.000+2%-31343250.000-30%-22854000.000-49%-13577025.000-70%
Usd Revenue--5380000.0001345000.000+300%2360691.500+128%3612738.300+49%3108294.150+73%
Usd Total Gains Per Share--3.8620.684+465%0.568+580%0.547+607%0.300+1189%
 EOD+2 -6MRQTTM+30 -4YOY+18 -165Y+26 -810Y+25 -9

4.2. Fundamental Score

Let's check the fundamental score of Xenon Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-17.070
Price to Book Ratio (EOD)Between0-13.292
Net Profit Margin (MRQ)Greater than0-8.317
Operating Margin (MRQ)Greater than0-9.980
Quick Ratio (MRQ)Greater than141.374
Current Ratio (MRQ)Greater than123.648
Debt to Asset Ratio (MRQ)Less than10.038
Debt to Equity Ratio (MRQ)Less than10.040
Return on Equity (MRQ)Greater than0.15-0.048
Return on Assets (MRQ)Greater than0.05-0.046
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Xenon Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.580
Ma 20Greater thanMa 5041.377
Ma 50Greater thanMa 10044.065
Ma 100Greater thanMa 20044.215
OpenGreater thanClose40.020
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Gross Profit  -506152-354-248-602-1,132-1,7346,2634,529



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets964,798
Total Liabilities36,877
Total Stockholder Equity927,921
 As reported
Total Liabilities 36,877
Total Stockholder Equity+ 927,921
Total Assets = 964,798

Assets

Total Assets964,798
Total Current Assets644,962
Long-term Assets319,836
Total Current Assets
Cash And Cash Equivalents 148,643
Short-term Investments 489,439
Net Receivables 874
Other Current Assets 6,006
Total Current Assets  (as reported)644,962
Total Current Assets  (calculated)644,962
+/-0
Long-term Assets
Property Plant Equipment 18,846
Long Term Investments 292,792
Long-term Assets Other 7,396
Long-term Assets  (as reported)319,836
Long-term Assets  (calculated)319,034
+/- 802

Liabilities & Shareholders' Equity

Total Current Liabilities27,273
Long-term Liabilities9,604
Total Stockholder Equity927,921
Total Current Liabilities
Short-term Debt 1,299
Accounts payable 8,598
Other Current Liabilities 17,376
Total Current Liabilities  (as reported)27,273
Total Current Liabilities  (calculated)27,273
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt9,604
Long-term Liabilities  (as reported)9,604
Long-term Liabilities  (calculated)9,604
+/-0
Total Stockholder Equity
Common Stock1,436,374
Retained Earnings -665,140
Accumulated Other Comprehensive Income -77
Other Stockholders Equity 156,764
Total Stockholder Equity (as reported)927,921
Total Stockholder Equity (calculated)927,921
+/-0
Other
Capital Stock1,436,374
Cash and Short Term Investments 638,082
Common Stock Shares Outstanding 69,968
Liabilities and Stockholders Equity 964,798
Net Debt -137,740
Net Invested Capital 927,921
Net Working Capital 617,689
Property Plant and Equipment Gross 30,097
Short Long Term Debt Total 10,903



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302012-12-31
> Total Assets 
63,305
0
54,487
0
50,712
54,144
87,418
79,403
76,527
69,944
63,949
61,152
55,687
73,371
67,487
60,786
54,226
46,359
46,121
37,762
65,436
130,455
122,428
114,550
105,892
98,904
147,697
237,043
210,676
199,128
189,186
290,671
274,711
264,353
572,007
558,059
807,380
775,813
754,146
719,868
684,899
671,093
964,798
964,798671,093684,899719,868754,146775,813807,380558,059572,007264,353274,711290,671189,186199,128210,676237,043147,69798,904105,892114,550122,428130,45565,43637,76246,12146,35954,22660,78667,48773,37155,68761,15263,94969,94476,52779,40387,41854,14450,712054,487063,305
   > Total Current Assets 
0
0
49,869
0
45,208
48,269
84,942
77,050
74,353
66,114
60,866
58,268
53,392
71,350
65,675
59,141
52,633
44,987
44,821
36,661
64,350
129,493
121,437
112,047
103,325
96,478
144,866
233,870
207,010
194,810
181,783
283,260
266,755
256,314
559,020
545,616
794,803
649,176
600,298
533,351
544,616
531,008
644,962
644,962531,008544,616533,351600,298649,176794,803545,616559,020256,314266,755283,260181,783194,810207,010233,870144,86696,478103,325112,047121,437129,49364,35036,66144,82144,98752,63359,14165,67571,35053,39258,26860,86666,11474,35377,05084,94248,26945,208049,86900
       Cash And Cash Equivalents 
60,162
0
37,950
0
35,087
33,731
72,026
65,917
64,346
65,469
58,651
56,064
35,210
54,135
17,095
20,160
23,090
14,688
20,486
17,200
47,435
87,962
67,754
52,180
37,075
37,671
24,755
60,508
44,199
15,100
45,009
87,985
82,930
87,809
175,688
116,541
369,987
103,489
57,242
69,512
64,552
99,574
148,643
148,64399,57464,55269,51257,242103,489369,987116,541175,68887,80982,93087,98545,00915,10044,19960,50824,75537,67137,07552,18067,75487,96247,43517,20020,48614,68823,09020,16017,09554,13535,21056,06458,65165,46964,34665,91772,02633,73135,087037,950060,162
       Short-term Investments 
0
0
11,326
0
9,623
14,205
12,015
9,464
9,354
0
0
0
15,528
15,356
47,051
37,867
28,606
29,084
23,181
17,878
15,835
39,166
51,552
58,249
64,726
56,932
116,603
169,163
158,555
175,827
131,988
186,718
177,593
161,816
376,086
421,399
418,251
534,696
534,845
457,531
475,048
427,100
489,439
489,439427,100475,048457,531534,845534,696418,251421,399376,086161,816177,593186,718131,988175,827158,555169,163116,60356,93264,72658,24951,55239,16615,83517,87823,18129,08428,60637,86747,05115,35615,5280009,3549,46412,01514,2059,623011,32600
       Net Receivables 
0
0
440
0
364
162
215
1,205
188
274
315
386
658
595
200
189
198
129
438
432
171
180
256
132
171
209
813
1,617
1,786
1,609
1,822
5,060
2,919
3,235
2,765
2,923
2,524
2,482
986
2,222
2,123
805
874
8748052,1232,2229862,4822,5242,9232,7653,2352,9195,0601,8221,6091,7861,6178132091711322561801714324381291981892005956583863152741881,205215162364044000
       Inventory 
0
0
0
0
0
0
0
0
-188
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1,786
0
0
0
0
0
0
0
0
0
-986
0
-2,123
-805
0
0-805-2,1230-986000000000-1,7860000000000000000000-18800000000
   > Long-term Assets 
0
0
4,618
0
5,504
5,875
2,476
2,353
2,174
3,830
3,083
2,884
2,295
2,021
1,812
1,645
1,593
1,372
1,300
1,101
1,086
962
991
2,503
2,567
2,426
2,831
3,173
3,666
4,318
7,403
7,411
7,956
8,039
12,987
12,443
12,577
126,636
153,848
186,517
140,283
140,085
319,836
319,836140,085140,283186,517153,848126,63612,57712,44312,9878,0397,9567,4117,4034,3183,6663,1732,8312,4262,5672,5039919621,0861,1011,3001,3721,5931,6451,8122,0212,2952,8843,0833,8302,1742,3532,4765,8755,50404,61800
       Property Plant Equipment 
2,602
0
1,879
0
2,024
1,999
2,476
2,353
2,174
2,130
1,989
1,790
1,663
1,542
1,404
1,376
1,308
1,154
1,070
1,101
1,086
962
991
2,431
2,451
2,248
2,593
2,987
3,376
3,840
6,880
6,897
7,412
7,228
12,522
12,236
12,266
12,133
16,906
18,072
19,362
19,733
18,846
18,84619,73319,36218,07216,90612,13312,26612,23612,5227,2287,4126,8976,8803,8403,3762,9872,5932,2482,4512,4319919621,0861,1011,0701,1541,3081,3761,4041,5421,6631,7901,9892,1302,1742,3532,4761,9992,02401,87902,602
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
113,989
128,682
160,265
112,592
112,407
292,792
292,792112,407112,592160,265128,682113,9890000000000000000000000000000000000000
       Other Assets 
0
0
2,739
0
3,480
3,876
0
0
0
1,700
1,094
1,094
632
479
408
269
285
218
230
0
0
0
105
72
116
178
238
186
290
478
523
514
544
11,493
465
4,753
4,041
1
143,658
172,310
123,369
123,280
306,194
306,194123,280123,369172,310143,65814,0414,75346511,493544514523478290186238178116721050002302182852694084796321,0941,0941,7000003,8763,48002,73900
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
72
116
178
238
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000002381781167200000000000000000000000
> Total Liabilities 
50,682
0
30,371
0
23,606
19,165
14,639
10,434
12,180
5,485
2,915
2,989
3,030
4,062
3,586
3,591
3,774
3,058
10,187
9,264
14,815
19,299
19,133
22,237
23,105
24,340
55,720
49,065
21,378
17,105
17,831
14,394
17,728
15,414
21,974
16,206
21,587
22,694
32,649
32,924
38,442
34,501
36,877
36,87734,50138,44232,92432,64922,69421,58716,20621,97415,41417,72814,39417,83117,10521,37849,06555,72024,34023,10522,23719,13319,29914,8159,26410,1873,0583,7743,5913,5864,0623,0302,9892,9155,48512,18010,43414,63919,16523,606030,371050,682
   > Total Current Liabilities 
19,196
0
18,203
0
17,231
16,343
14,286
10,254
12,016
5,336
2,782
2,872
2,929
3,976
3,516
3,591
3,774
3,058
4,083
3,788
3,094
4,413
4,119
6,376
9,330
11,697
43,379
48,524
21,055
16,917
14,781
11,492
14,982
12,856
14,322
7,982
13,736
15,537
22,702
22,491
28,159
24,744
27,273
27,27324,74428,15922,49122,70215,53713,7367,98214,32212,85614,98211,49214,78116,91721,05548,52443,37911,6979,3306,3764,1194,4133,0943,7884,0833,0583,7743,5913,5163,9762,9292,8722,7825,33612,01610,25414,28616,34317,231018,203019,196
       Short-term Debt 
0
0
0
0
0
0
0
0
1,406
0
0
0
0
0
0
0
0
0
700
1,400
11,721
14,886
15,014
582
2,654
3,774
4,818
15,832
594
596
265
270
759
686
605
8,224
7,851
7,157
488
1,194
1,223
11,003
1,299
1,29911,0031,2231,1944887,1577,8518,22460568675927026559659415,8324,8183,7742,65458215,01414,88611,7211,4007000000000001,40600000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
700
1,400
11,721
0
0
582
2,067
3,616
4,650
15,676
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000015,6764,6503,6162,0675820011,7211,400700000000000000000000
       Accounts payable 
821
0
391
0
620
511
553
632
872
817
1,088
1,023
655
512
1,463
1,165
1,314
809
1,253
473
853
959
665
1,071
1,498
1,371
2,473
3,217
1,633
2,198
3,041
2,132
3,278
3,085
3,824
1,659
3,178
3,082
8,491
11,412
12,026
6,097
8,598
8,5986,09712,02611,4128,4913,0823,1781,6593,8243,0853,2782,1323,0412,1981,6333,2172,4731,3711,4981,0716659598534731,2538091,3141,1651,4635126551,0231,08881787263255351162003910821
       Other Current Liabilities 
18,375
0
1,892
0
1,529
2,310
2,111
898
4,103
2,006
1,537
1,849
2,274
3,464
2,053
2,426
2,460
2,249
2,130
1,915
2,241
3,454
3,454
582
5,178
6,552
6,345
4,867
6,136
6,677
7,833
5,448
7,920
6,883
9,893
6,323
2,707
5,298
13,723
9,885
1,223
13,741
17,376
17,37613,7411,2239,88513,7235,2982,7076,3239,8936,8837,9205,4487,8336,6776,1364,8676,3456,5525,1785823,4543,4542,2411,9152,1302,2492,4602,4262,0533,4642,2741,8491,5372,0064,1038982,1112,3101,52901,892018,375
   > Long-term Liabilities 
0
0
12,168
0
6,375
2,822
353
180
164
149
133
117
101
86
70
70
0
0
6,104
5,476
11,721
14,886
15,014
15,861
13,775
12,643
12,341
541
323
188
3,050
2,902
2,746
2,558
7,652
8,224
7,851
7,157
9,947
10,433
10,283
9,757
9,604
9,6049,75710,28310,4339,9477,1577,8518,2247,6522,5582,7462,9023,05018832354112,34112,64313,77515,86115,01414,88611,7215,4766,104007070861011171331491641803532,8226,375012,16800
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,104
5,476
11,721
14,886
15,014
15,139
13,202
11,786
10,889
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000010,88911,78613,20215,13915,01414,88611,7215,4766,104000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
-1,406
0
0
0
0
0
0
0
0
0
-700
-1,400
-11,721
-14,886
-15,014
722
-1,494
-2,759
-3,907
-15,135
323
188
3,050
2,902
2,746
2,558
7,652
0
0
0
9,947
10,433
10,283
0
9,604
9,604010,28310,4339,9470007,6522,5582,7462,9023,050188323-15,135-3,907-2,759-1,494722-15,014-14,886-11,721-1,400-700000000000-1,40600000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
72
116
178
238
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000002381781167200000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
722
573
857
1,452
0
323
188
3,050
2,902
2,746
2,558
7,652
8,224
7,851
7,157
9,947
10,433
10,283
9,757
0
09,75710,28310,4339,9477,1577,8518,2247,6522,5582,7462,9023,05018832301,45285757372200000000000000000000000
       Deferred Long Term Liability 
0
0
2,739
0
0
2,822
353
180
164
149
133
117
101
86
70
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000070861011171331491641803532,822002,73900
> Total Stockholder Equity
12,623
0
24,116
0
27,106
34,979
72,779
68,969
64,347
64,459
61,034
58,163
52,657
69,309
63,901
57,195
50,452
43,301
35,934
28,498
50,621
111,156
103,295
92,313
82,787
74,564
91,977
187,978
189,298
182,023
171,355
276,277
256,983
248,939
550,033
541,853
785,793
753,119
721,497
686,944
646,457
636,592
927,921
927,921636,592646,457686,944721,497753,119785,793541,853550,033248,939256,983276,277171,355182,023189,298187,97891,97774,56482,78792,313103,295111,15650,62128,49835,93443,30150,45257,19563,90169,30952,65758,16361,03464,45964,34768,96972,77934,97927,106024,116012,623
   Common Stock
6,008
0
6,147
0
108,782
6,198
147,157
147,508
147,824
148,359
148,634
148,728
148,867
172,886
173,246
173,829
173,841
173,841
173,841
147,887
177,012
261,655
265,923
266,040
266,062
266,425
294,244
397,307
397,652
397,654
397,748
498,334
499,351
504,386
783,170
800,307
1,061,690
1,064,698
1,065,136
1,073,150
1,083,008
1,121,968
1,436,374
1,436,3741,121,9681,083,0081,073,1501,065,1361,064,6981,061,690800,307783,170504,386499,351498,334397,748397,654397,652397,307294,244266,425266,062266,040265,923261,655177,012147,887173,841173,841173,841173,829173,246172,886148,867148,728148,634148,359147,824147,508147,1576,198108,78206,14706,008
   Retained Earnings Total Equity000-524,474-482,747-445,352-408,202-377,044-357,374-331,810-316,365-294,256-278,492-266,169-257,3140-249,655-238,279-229,408-219,401-207,885-199,327-184,944-177,143-173,388-165,323-157,581-150,201-142,681-136,704-128,972-122,956-119,693-115,754-111,801-112,930-103,734-104,95800000
   Accumulated Other Comprehensive Income 
0
0
2,511
0
2,521
1,009
-990
-990
-990
-990
-990
-990
-990
-990
-990
-990
-990
-990
-990
-990
-990
-990
-990
-990
-990
-990
-990
-990
-990
-990
-990
-990
-990
-990
-990
-990
-990
-2,955
-3,000
-1,820
-3,299
-2,953
-77
-77-2,953-3,299-1,820-3,000-2,955-990-990-990-990-990-990-990-990-990-990-990-990-990-990-990-990-990-990-990-990-990-990-990-990-990-990-990-990-990-990-9901,0092,52102,51100
   Capital Surplus 
0
0
0
0
0
30,242
30,346
29,083
29,314
32,844
33,083
33,381
33,752
34,117
34,326
34,557
35,182
35,773
36,471
36,919
37,718
37,886
38,515
38,932
39,391
39,676
40,646
41,068
42,218
43,796
45,357
65,457
67,255
69,621
117,495
119,580
133,295
136,728
142,108
140,088
0
0
0
000140,088142,108136,728133,295119,580117,49569,62167,25565,45745,35743,79642,21841,06840,64639,67639,39138,93238,51537,88637,71836,91936,47135,77335,18234,55734,32634,11733,75233,38133,08332,84429,31429,08330,34630,24200000
   Treasury Stock0000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
29,722
0
29,952
30,242
30,346
-117,058
-118,510
-115,515
-115,551
-115,347
-115,115
-138,769
-138,920
-139,272
-138,659
-138,068
-137,370
36,919
37,718
37,886
38,515
38,932
39,391
39,676
40,646
41,068
42,218
43,796
45,357
65,457
67,255
69,621
117,495
119,580
133,295
136,728
142,108
140,088
138,683
137,974
156,764
156,764137,974138,683140,088142,108136,728133,295119,580117,49569,62167,25565,45745,35743,79642,21841,06840,64639,67639,39138,93238,51537,88637,71836,919-137,370-138,068-138,659-139,272-138,920-138,769-115,115-115,347-115,551-115,515-118,510-117,05830,34630,24229,952029,72200



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-3,541
Gross Profit-3,541-3,541
 
Operating Income (+$)
Gross Profit-3,541
Operating Expense-210,513
Operating Income-214,054-214,054
 
Operating Expense (+$)
Research Development167,512
Selling General Administrative46,542
Selling And Marketing Expenses3,541
Operating Expense210,513217,595
 
Net Interest Income (+$)
Interest Income23,392
Interest Expense-0
Other Finance Cost-0
Net Interest Income23,392
 
Pretax Income (+$)
Operating Income-214,054
Net Interest Income23,392
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-182,685-245,423
EBIT - interestExpense = -214,054
-182,685
-182,393
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-214,054-182,685
Earnings Before Interest and Taxes (EBITDA)-210,513
 
After tax Income (+$)
Income Before Tax-182,685
Tax Provision-1,052
Net Income From Continuing Ops-175,045-183,737
Net Income-182,393
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses214,054
Total Other Income/Expenses Net31,369-23,392
 

Technical Analysis of Xenon Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Xenon Pharmaceuticals Inc. The general trend of Xenon Pharmaceuticals Inc is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Xenon Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Xenon Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 40.97 < 43.30 < 44.63.

The bearish price targets are: 36.97 > 34.25 > 27.99.

Tweet this
Xenon Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Xenon Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Xenon Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Xenon Pharmaceuticals Inc. The current macd is -1.02235919.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Xenon Pharmaceuticals Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Xenon Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Xenon Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Xenon Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartXenon Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Xenon Pharmaceuticals Inc. The current adx is 32.95.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Xenon Pharmaceuticals Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Xenon Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Xenon Pharmaceuticals Inc. The current sar is 41.82.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Xenon Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Xenon Pharmaceuticals Inc. The current rsi is 41.58. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Xenon Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartXenon Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Xenon Pharmaceuticals Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Xenon Pharmaceuticals Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Xenon Pharmaceuticals Inc Daily Stochastic Oscillator ChartXenon Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Xenon Pharmaceuticals Inc. The current cci is -83.19073408.

Xenon Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartXenon Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Xenon Pharmaceuticals Inc. The current cmo is -13.02187516.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Xenon Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartXenon Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Xenon Pharmaceuticals Inc. The current willr is -62.92134831.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Xenon Pharmaceuticals Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Xenon Pharmaceuticals Inc Daily Williams %R ChartXenon Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Xenon Pharmaceuticals Inc. The current atr is 1.47074725.

Xenon Pharmaceuticals Inc Daily Average True Range (ATR) ChartXenon Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Xenon Pharmaceuticals Inc. The current obv is 15,410,864.

Xenon Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartXenon Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Xenon Pharmaceuticals Inc. The current mfi is 40.19.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Xenon Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartXenon Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Xenon Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-09ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-26STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Xenon Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Xenon Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.580
Ma 20Greater thanMa 5041.377
Ma 50Greater thanMa 10044.065
Ma 100Greater thanMa 20044.215
OpenGreater thanClose40.020
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Xenon Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Xenon Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Xenon Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Xenon Pharmaceuticals Inc

I send you an email if I find something interesting about Xenon Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Xenon Pharmaceuticals Inc.

Receive notifications about Xenon Pharmaceuticals Inc in your mailbox!